Ajooni Biotech Limited — Results, 09-07-2025: Reply to Clarification- Financial results

Ajooni Biotech Limited has announced a board meeting on June 30, 2025, to approve the financial results for the quarter and half-year.

For the fiscal year ended March 31, 2025, revenue from operations stood at Rs. 29.27 Cr, up from Rs. 19.58 Cr in the previous year. Other income was Rs. 1.34 Cr, driving total income to Rs. 30.61 Cr compared with Rs. 19.83 Cr a year ago.

Total expenses increased to Rs. 28.70 Cr from Rs. 18.34 Cr, mainly due to higher material costs (Rs. 22.59 Cr vs Rs. 15.26 Cr) and employee benefits expenses. Profit before tax reached Rs. 1.91 Cr, improving from Rs. 1.50 Cr last year. After tax and adjustments, net profit was Rs. 1.54 Cr, up from Rs. 0.91 Cr previously.

Earnings per share (EPS) were Rs. 0.09 (basic and diluted) based on a face value of Rs. 2 per share. The company’s equity share capital doubled to Rs. 34.45 Cr after a rights issue.

Total assets rose to Rs. 95.05 Cr from Rs. 47.52 Cr, reflecting increased investments, inventories, and receivables. Borrowings remained low at Rs. 1.94 Cr. Other equity increased to Rs. 53.63 Cr, supporting the company’s improved net worth and financial position.

The statutory audit concluded with an unmodified opinion, confirming the financial statements provide a fair and true view with effective internal controls in place. No material uncertainties or disputes were noted.

Overall, Ajooni Biotech has demonstrated steady top-line growth with moderate margin expansion, supported by better working capital management and fresh equity infusion.